vs
奔特力系统（BSY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是奔特力系统的2.0倍（$772.1M vs $391.6M），奔特力系统净利率更高（15.0% vs 12.7%，领先2.2%），奔特力系统同比增速更快（11.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $136.2M），过去两年Revvity的营收复合增速更高（9.0% vs 7.7%）
奔特力系统是总部位于美国的软件开发企业，面向全球基础设施的设计、建造及运营全周期，提供软件产品授权、销售及相关技术支持服务。旗下产品覆盖建筑、工厂、土木、地理空间等领域，广泛应用于建筑工程施工及运营场景，支撑各类大型建成资产的全生命周期管理。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BSY vs RVTY — 直观对比
营收规模更大
RVTY
是对方的2.0倍
$391.6M
营收增速更快
BSY
高出6.1%
5.9%
净利率更高
BSY
高出2.2%
12.7%
自由现金流更多
RVTY
多$25.6M
$136.2M
两年增速更快
RVTY
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $391.6M | $772.1M |
| 净利润 | $58.6M | $98.4M |
| 毛利率 | 81.9% | — |
| 营业利润率 | 20.0% | 14.5% |
| 净利率 | 15.0% | 12.7% |
| 营收同比 | 11.9% | 5.9% |
| 净利润同比 | 17.1% | 3.9% |
| 每股收益（稀释后） | $0.17 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSYRVTY
| Q4 25 | $391.6M | $772.1M | ||
| Q3 25 | $375.5M | $698.9M | ||
| Q2 25 | $364.1M | $720.3M | ||
| Q1 25 | $370.5M | $664.8M | ||
| Q4 24 | $349.8M | $729.4M | ||
| Q3 24 | $335.2M | $684.0M | ||
| Q2 24 | $330.3M | $691.7M | ||
| Q1 24 | $337.8M | $649.9M |
净利润BSYRVTY
| Q4 25 | $58.6M | $98.4M | ||
| Q3 25 | $57.4M | $46.7M | ||
| Q2 25 | $70.5M | $53.9M | ||
| Q1 25 | $91.4M | $42.2M | ||
| Q4 24 | $50.1M | $94.6M | ||
| Q3 24 | $42.3M | $94.4M | ||
| Q2 24 | $72.0M | $55.4M | ||
| Q1 24 | $70.3M | $26.0M |
毛利率BSYRVTY
| Q4 25 | 81.9% | — | ||
| Q3 25 | 80.8% | 53.6% | ||
| Q2 25 | 81.1% | 54.5% | ||
| Q1 25 | 82.3% | 56.5% | ||
| Q4 24 | 80.6% | — | ||
| Q3 24 | 80.7% | 56.3% | ||
| Q2 24 | 80.9% | 55.7% | ||
| Q1 24 | 81.7% | 54.6% |
营业利润率BSYRVTY
| Q4 25 | 20.0% | 14.5% | ||
| Q3 25 | 22.5% | 11.7% | ||
| Q2 25 | 23.2% | 12.6% | ||
| Q1 25 | 31.1% | 10.9% | ||
| Q4 24 | 17.6% | 16.3% | ||
| Q3 24 | 20.5% | 14.3% | ||
| Q2 24 | 24.3% | 12.4% | ||
| Q1 24 | 27.2% | 6.8% |
净利率BSYRVTY
| Q4 25 | 15.0% | 12.7% | ||
| Q3 25 | 15.3% | 6.7% | ||
| Q2 25 | 19.4% | 7.5% | ||
| Q1 25 | 24.7% | 6.4% | ||
| Q4 24 | 14.3% | 13.0% | ||
| Q3 24 | 12.6% | 13.8% | ||
| Q2 24 | 21.8% | 8.0% | ||
| Q1 24 | 20.8% | 4.0% |
每股收益（稀释后）BSYRVTY
| Q4 25 | $0.17 | $0.86 | ||
| Q3 25 | $0.18 | $0.40 | ||
| Q2 25 | $0.22 | $0.46 | ||
| Q1 25 | $0.28 | $0.35 | ||
| Q4 24 | $0.15 | $0.77 | ||
| Q3 24 | $0.13 | $0.77 | ||
| Q2 24 | $0.22 | $0.45 | ||
| Q1 24 | $0.22 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $123.3M | $919.9M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $1.2B | $7.3B |
| 总资产 | $3.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.05× | — |
8季度趋势，按日历期对齐
现金及短期投资BSYRVTY
| Q4 25 | $123.3M | $919.9M | ||
| Q3 25 | $165.4M | $931.4M | ||
| Q2 25 | $89.6M | $991.8M | ||
| Q1 25 | $83.6M | $1.1B | ||
| Q4 24 | $64.0M | $1.2B | ||
| Q3 24 | $72.2M | $1.2B | ||
| Q2 24 | $51.3M | $2.0B | ||
| Q1 24 | $141.6M | $1.7B |
总债务BSYRVTY
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.4B | — |
股东权益BSYRVTY
| Q4 25 | $1.2B | $7.3B | ||
| Q3 25 | $1.2B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.0B | $7.7B | ||
| Q3 24 | $1.0B | $7.9B | ||
| Q2 24 | $984.5M | $7.9B | ||
| Q1 24 | $932.6M | $7.8B |
总资产BSYRVTY
| Q4 25 | $3.6B | $12.2B | ||
| Q3 25 | $3.5B | $12.1B | ||
| Q2 25 | $3.4B | $12.4B | ||
| Q1 25 | $3.4B | $12.4B | ||
| Q4 24 | $3.4B | $12.4B | ||
| Q3 24 | $3.4B | $12.8B | ||
| Q2 24 | $3.3B | $13.4B | ||
| Q1 24 | $3.4B | $13.4B |
负债/权益比BSYRVTY
| Q4 25 | 1.05× | — | ||
| Q3 25 | 1.04× | — | ||
| Q2 25 | 1.07× | — | ||
| Q1 25 | 1.13× | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 1.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $141.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $136.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 34.8% | 21.0% |
| 资本支出强度资本支出/营收 | 1.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.41× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $520.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BSYRVTY
| Q4 25 | $141.6M | $182.0M | ||
| Q3 25 | $116.4M | $138.5M | ||
| Q2 25 | $61.1M | $134.3M | ||
| Q1 25 | $219.4M | $128.2M | ||
| Q4 24 | $81.6M | $174.2M | ||
| Q3 24 | $86.1M | $147.9M | ||
| Q2 24 | $62.6M | $158.6M | ||
| Q1 24 | $205.0M | $147.6M |
自由现金流BSYRVTY
| Q4 25 | $136.2M | $161.8M | ||
| Q3 25 | $110.7M | $120.0M | ||
| Q2 25 | $57.0M | $115.5M | ||
| Q1 25 | $216.4M | $112.2M | ||
| Q4 24 | $76.1M | $149.8M | ||
| Q3 24 | $84.3M | $125.6M | ||
| Q2 24 | $59.5M | $136.6M | ||
| Q1 24 | $201.4M | $129.7M |
自由现金流率BSYRVTY
| Q4 25 | 34.8% | 21.0% | ||
| Q3 25 | 29.5% | 17.2% | ||
| Q2 25 | 15.7% | 16.0% | ||
| Q1 25 | 58.4% | 16.9% | ||
| Q4 24 | 21.7% | 20.5% | ||
| Q3 24 | 25.1% | 18.4% | ||
| Q2 24 | 18.0% | 19.7% | ||
| Q1 24 | 59.6% | 20.0% |
资本支出强度BSYRVTY
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 1.5% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 0.8% | 2.4% | ||
| Q4 24 | 1.6% | 3.4% | ||
| Q3 24 | 0.5% | 3.3% | ||
| Q2 24 | 0.9% | 3.2% | ||
| Q1 24 | 1.1% | 2.7% |
现金转化率BSYRVTY
| Q4 25 | 2.41× | 1.85× | ||
| Q3 25 | 2.03× | 2.97× | ||
| Q2 25 | 0.87× | 2.49× | ||
| Q1 25 | 2.40× | 3.03× | ||
| Q4 24 | 1.63× | 1.84× | ||
| Q3 24 | 2.03× | 1.57× | ||
| Q2 24 | 0.87× | 2.87× | ||
| Q1 24 | 2.92× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSY
| Enterprise License Subscriptions | $163.4M | 42% |
| Term License Subscriptions | $122.7M | 31% |
| SELECT Subscriptions | $70.6M | 18% |
| Professional Services Other | $17.2M | 4% |
| Perpetual Licenses | $14.3M | 4% |
| Professional Services Recurring | $3.5M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
